Focused On-demand Library for Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q96RQ3

UPID:
MCCA_HUMAN

ALTERNATIVE NAMES:
3-methylcrotonyl-CoA carboxylase 1; 3-methylcrotonyl-CoA carboxylase biotin-containing subunit; 3-methylcrotonyl-CoA:carbon dioxide ligase subunit alpha

ALTERNATIVE UPACC:
Q96RQ3; Q59ES4; Q9H959; Q9NS97

BACKGROUND:
The enzyme Methylcrotonoyl-CoA carboxylase subunit alpha, located in mitochondria, is essential for breaking down leucine, an amino acid. It is also known as 3-methylcrotonyl-CoA carboxylase biotin-containing subunit, indicating its biotin dependency for function.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Methylcrotonoyl-CoA carboxylase subunit alpha could open doors to potential therapeutic strategies. Its involvement in 3-methylcrotonoyl-CoA carboxylase 1 deficiency underlines its importance in human health and disease management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.